School of Nursing, McMaster University, Hamilton.
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton.
Eur J Gastroenterol Hepatol. 2019 Oct;31(10):1192-1199. doi: 10.1097/MEG.0000000000001498.
The primary objective was to examine the trends in treatment modalities and the respective survival rates for esophageal cancer in the province of Ontario, Canada.
This is a population-based study of all esophageal cancer cases diagnosed in Ontario between 2007 and 2015, including squamous cell carcinoma and adenocarcinoma, with known disease stage. Other characteristics include sex, age, date of diagnosis, and treatment modalities. Treatment modalities were classified as no-treatment, radiation only or chemotherapy only, chemoradiation, and surgical resection.
In total, 2572 patients were identified with esophageal cancer from 2007 to 2015, of which 2014 (78.3%) were male. The mean age at diagnosis was 66.6 (SD = 11.7) years. Survival rate increased over time in patients who underwent chemoradiation or surgical resection but remained unchanged for the radiation-only or chemotherapy-only group and decreased for the no-treatment group. Survival considerably improved (15-20%) for patients with stages I-III disease.
The positive trends in the survival rate for esophageal patients could be due to adoption of multimodal therapy. Despite a lower proportion of advanced disease among patients over 80, they received less curative treatments compared with other age groups. Further studies are required to identify strategies to maximize survival for patients with stage IV disease, and patients 80 years and older.
本研究旨在分析加拿大安大略省食管癌的治疗方式变化趋势及其生存率。
这是一项基于人群的研究,纳入了 2007 年至 2015 年间安大略省所有经诊断患有食管癌(包括鳞状细胞癌和腺癌)且已知疾病分期的患者。其他特征包括性别、年龄、诊断日期和治疗方式。治疗方式分为未治疗、单纯放疗或单纯化疗、放化疗和手术切除。
共确定了 2572 例 2007 年至 2015 年间的食管癌患者,其中 2014 年(78.3%)为男性。诊断时的平均年龄为 66.6(SD=11.7)岁。接受放化疗或手术切除的患者生存率随时间推移而提高,但单纯放疗或化疗组的生存率保持不变,未治疗组的生存率下降。I-III 期患者的生存率显著提高(15-20%)。
食管癌患者生存率的积极趋势可能归因于多模式治疗的采用。尽管 80 岁以上患者的晚期疾病比例较低,但与其他年龄组相比,他们接受的根治性治疗较少。需要进一步研究以确定针对 IV 期疾病和 80 岁及以上患者的生存最大化策略。